long intergenic non-protein coding RNA 2862Genealiases: []
Q-omics provides the consensus-scored LINC02862 profile across patient tissues and cancer cell-line models. LINC02862 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC02862 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, LINC02862 RNA expression shows 6,881 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, BLCA, and STAD as cancer lineages where LINC02862 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02862 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02862 survival associations across molecular data types. LINC02862 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02862 RNA expression–survival associations across cancer types. High LINC02862 expression shows unfavorable associations in KIRP, KIRC, UVM, SKCM, UCEC and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC02862 RNA expression.
This table summarizes LINC02862 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02862. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02862 shows higher tumor expression in BLCA, LUAD, THCA, BRCA, HNSC and LUSC. The BLCA box plot shows higher LINC02862 RNA expression in tumor versus normal tissue (log2 FC = +0.821, t-test p = .003).
This table shows molecular features associated with LINC02862 in patient tissues and cancer cell lines. In patient samples, LINC02862 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
